MONTREAL, April 11, 2023 /PRNewswire/ – MY01, Inc., a medical technology company that uses microsensors to aid physicians in diagnosing compartment syndrome, today announced it has raised a $12.5 million USD Series A funding round. The round is led by Investissement Quebec, with participation from Desjardins Capital and Fondaction. The funding will be used to expand commercialization activities in the United States.
“This investment will support MY01’s goal of becoming the gold standard in the diagnosis of compartment syndrome,” said Charles Allan, Chief Executive Officer of MY01. “Our growth has been significant since our launch in the United States and this funding will allow us to accelerate our development while improving patient outcomes.”
“The technology developed by MY01 has great potential to transform the diagnosis of compartment syndrome as well as the quality of care. Investissement Québec is delighted to join this round of financing, which will support the commercialization and development of their technology. Our support demonstrates our desire to support promising companies in the life sciences sector, such as MY01, in order to continue to develop this important and strategic sector of our economy,” states Guy LeBlanc, President and CEO of Investissement Québec.